Abstract
Nucleic acid-based bioactive substances have recently emerged as a new class of next-generation therapeutics, but their development has been limited by their relatively weak delivery into target cells. Cationic liposomes have been studied as a means to enhance the stability of nucleic acid therapeutics in the bloodstream and improve their cellular delivery. As nucleic acid therapeutics, siRNA and plasmid DNA have been extensively tested for delivery using cationic liposomes. This review discusses recent progress in the application of cationic liposomes for the delivery of nucleic acid therapeutics.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
